Abstract:Background Hepatocellular carcinoma (HCC) presents one of the major health threats in China today. A better understanding of the molecular genetics underlying malignant transformation of hepatocytes is critical to success in the battle against this disease. The methylation state of C5 of the cytosine in the CpG di-nucleotide that is enriched within or near the promoter region of over 50 % of the polymerase II genes has a drastic effect on transcription of these genes. Changes in the methylation profile of the promoters represent an alternative to genetic lesions as causative factors for the tumor-specific aberrant expression of the genes. Methods We have used the methylation specific PCR method in conjunction with DNA sequencing to assess the methylation state of the promoter CpG islands of twenty genes. Aberrant expression of these genes have been attributed to the abnormal methylation profile of the corresponding promoter CpG islands in human tumors. Results While the following sixteen genes remained the unmethylated in all tumor and normal tissues: CDH1, APAF1, hMLH1, BRCA1, hTERC, VHL, RARβ, TIMP3, DAPK1, SURVIVIN, p14 ARF , RB1, p15 INK4b , APC, RASSF1c and PTEN, varying degrees of tumor specific hypermethylation were associated with the p16 INK4a , RASSF1a, CASP8 and CDH13 genes. For instance, the p16 INK4a was highly methylated in HCC (17/29, 58.6%) and less significantly methylated in non-cancerous tissue (4/29. 13.79%). The RASSF1a was fully methylated in all tumor tissues (29/29, 100%), and less frequently methylated in corresponding non-cancerous tissue (24/29, 82.75%). Conclusions Furthermore, co-existence of methylated with unmethylated DNA in some cases suggested that both genetic and epigenetic (CpG methylation) mechanisms may act in concert to inactivate the p16 INK4a and RASSF1a in HCC. Finally, we found a significant association of cirrhosis with hypermethylation of the p16 INK4a and hypomethylation of the CDH13 genes. For the first time, the survey was carried out on such an extent that it would not only provide new insights into the molecular mechanisms underscoring the aberrant expression of the genes in this study in HCC, but also offer essential information required for a good methylation-based diagnosis of HCC.

Hypermethylation of ACP1 , BMP4 , and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance

Aberrant Methylation Status of SPG20 Promoter in Hepatocellular Carcinoma: A Potential Tumor Metastasis Biomarker.

Association of Low P16ink4a and P15ink4b Mrnas Expression with Their Cpg Islands Methylation with Human Hepatocellular Carcinogenesis

Quantitative Analysis of APC Promoter Methylation in Hepatocellular Carcinoma and Its Prognostic Implications

Aberrant Methylation of TRIM58 in Hepatocellular Carcinoma and Its Potential Clinical Implication.

Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma

The Association Between Methylation Patterns of DNAH17 and Clinicopathological Factors in Hepatocellular Carcinoma

[Aberrant Methylation of Multiple Genes and Its Clinical Implication in Hepatocellular Carcinoma].

Quantificational Methylation Analysis of APC and AXIN2 in HBV-related Hepatocellular Carcinoma

Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients.

Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis

Methylation Patterns of RASA3 Associated with Clinicopathological Factors in Hepatocellular Carcinoma.

Integrated Analyses of DNA Methylation and Hydroxymethylation Reveal Tumor Suppressive Roles of ECM1 , ATF5 , and EOMES in Human Hepatocellular Carcinoma

Hypermethylation-repressed methionine adenosyltransferase 1A as a potential biomarker for hepatocellular carcinoma.

Hypermethylation leads to bone morphogenetic protein 6 downregulation in hepatocellular carcinoma.

Genome-wide DNA methylation analysis identifies candidate epigenetic markers and drivers of hepatocellular carcinoma.

Detecting abnormal methylation of tumor suppressor genes GSTP1 , P16 , RIZ1 , and RASSF1A in hepatocellular carcinoma and its clinical significance.

Aberrant Promoter Methylation Profiles of Tumor Suppressor Genes in Hepatocellular Carcinoma.

Methylation Profile of the Promoter CpG Islands of 14 “Drug-Resistance” Genes in Hepatocellular Carcinoma

Meta-Analysis Of Dna Methylation Biomarkers In Hepatocellular Carcinoma

A New Approach to Evaluating Aberrant DNA Methylation Profiles in Hepatocellular Carcinoma as Potential Biomarkers